PP442 - PERSISTENT LOW MUSCLE MASS IS ASSOCIATED WITH HIGHER MORTALITY RISK IN LOCALLY ADVANCED CERVICAL CANCER

PP442

PERSISTENT LOW MUSCLE MASS IS ASSOCIATED WITH HIGHER MORTALITY RISK IN LOCALLY ADVANCED CERVICAL CANCER

L. D. Galván-Cota¹, L. D. Galván-Cota¹, A. D. Castro-Eguiluz^1,2, M. Delgadillo-González³, A. A. Rueda-Escalona⁴, D. Isla-Ortiz^3,5, J. Luvián-Morales^3,*

¹Subdirección de Investigación Clínica, Instituto Nacional de Cancerología (INCan), ²Investigadora por México, Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), ³MICAELA Program, Instituto Nacional de Cancerología (INCan), Mexico City, ⁴Masters in Medical Sciences Program, Universidad Anáhuac Mexico, Huixquilucan, ⁵Gynecologic Oncology Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

Rationale: Low muscle mass (LMM) in patients with locally advanced cervical cancer (LACC) has been consistently associated with adverse clinical outcomes. However, the impact of concurrent chemoradiotherapy (CRT) on body composition and whether treatment-related changes in muscle mass influence overall survival (OS) remain unclear. This study aimed to evaluate longitudinal changes in body composition and their association with OS in women with LACC.

Methods: This prospective cohort study included patients with LACC undergoing CRT. Body composition was assessed at diagnosis and 3 months after treatment using computed tomography at the L3 level. LMM was defined according to established cut-offs. A Cox proportional hazards model was used to identify variables independently associated with OS.

Results: A total of 292 patients were included. At baseline, the prevalence of LMM was 18.8% (n = 55). Changes in body composition at 3 months post-CRT are presented in Table 1.
In multivariable analysis, persistent LMM (at both times) was significantly associated with increased mortality risk (HR = 2.07; 95% CI: 1.05–4.07; p = 0.035), compared with patients that have normal muscle mass at least at one time point.

Table 1 Muscle mass before and after concurrent chemoradiotherapy in patients with locally advanced cervical cancer.

Conclusion: Persistent LMM is an independent predictor of mortality in patients with LACC. These findings highlight the clinical relevance of muscle mass assessment and support the development of targeted nutritional and exercise interventions aimed at preserving muscle mass and potentially improving survival outcomes.

Disclosure of Interest: None declared